Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines

@inproceedings{Klein2017CergutuzumabA,
  title={Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines},
  author={Christian Klein and Inja Waldhauer and Valeria G. Nicolini and Anne Freimoser-Grundschober and Tapan K. Nayak and Danielle J. Vugts and Corrie S Dunn and Marije Bolijn and Joerg Benz and Martine Stihle and Sabine Lang and Michaele Roemmele and Thomas Hofer and Erwin van Puijenbroek and David Wittig and Samuel Moser and Oliver Ast and Peter Bruenker and Ingo H. Gorr and Sebastian Neumann and Maria Cristina de Vera Mudry and Heather Hinton and Flavio Crameri and Jose Saro and Stefan Evers and Christian Gerdes and Marina Bacac and Guus van Dongen and Ekkehard Moessner and Pablo Uma{\~n}a},
  booktitle={Oncoimmunology},
  year={2017}
}
We developed cergutuzumab amunaleukin (CEA-IL2v, RG7813), a novel monomeric CEA-targeted immunocytokine, that comprises a single IL-2 variant (IL2v) moiety with abolished CD25 binding, fused to the C-terminus of a high affinity, bivalent carcinoembryonic antigen (CEA)-specific antibody devoid of Fc-mediated effector functions. Its molecular design aims to (i) avoid preferential activation of regulatory T-cells vs. immune effector cells by removing CD25 binding; (ii) increase the therapeutic… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 24 CITATIONS

Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2018
VIEW 3 EXCERPTS
CITES BACKGROUND

Combination treatment with hypofractionated radiotherapy plus IL-2/anti-IL-2 complexes and its theranostic evaluation

Hua Jing, Michael Hettich, +3 authors Gabriele Niedermann
  • Journal for ImmunoTherapy of Cancer
  • 2019
VIEW 2 EXCERPTS
CITES BACKGROUND

Dual Function pH Responsive Bispecific Antibodies for Tumor Targeting and Antigen Depletion in Plasma

Jan P. Bogen, Steffen C. Hinz, +4 authors Harald Kolmar
  • Front. Immunol.
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 66 REFERENCES

Human IL-2 mutein with higher antitumor efficacy than wild type IL-2.

  • Journal of immunology
  • 2013
VIEW 15 EXCERPTS
HIGHLY INFLUENTIAL

A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2016